Centre for Innovation
87 St David Street PO Box 56
Dunedin 9016
New Zealand
64 3 479 5800
https://www.pacificedgedx.com
Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Peter Meintjes | Chief Executive Officer | N/A | N/A | N/A |
Mr. Grant Gibson | Chief Financial Officer | N/A | N/A | N/A |
Mr. Darrell Morgan | Chief Operating Officer | N/A | N/A | N/A |
Dr. Justin Harvey | Chief Technology Officer | N/A | N/A | N/A |
Prof. Parry Guilford Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | 123,93k | N/A | N/A |
Mr. Andrew McIntosh | Chief Digital Officer | N/A | N/A | N/A |
Glen Costin | President of Asia Pacific | N/A | N/A | N/A |
Dr. Tamer Aboushwareb | Chief Medical Officer | N/A | N/A | N/A |
Mr. David Levison | Executive Chairman & President of Pacific Edge Diagnostics USA | 49,02k | N/A | 1960 |
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. The company is also developing Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, it is developing products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Pacific Edge Limiteds ISS Governance QualityScore, Stand 1. Juni 2024, lautet 4. Die grundlegenden Scores sind Audit: 7, Vorstand: 2, Shareholderrechte: 7, Kompensation: 8.